Exploration of effects of galvanic vestibular stimulation on circadian rhythms and its associations with sleep and spatial memory in patients with breast cancer: The ICANSLEEP-2 protocol

• DOI: 10.1371/journal.pone.0306462
• Publication Date: 2024-07-31T19:00:04Z
• Authors: Melvin Galin; Laura de Girolamo; Bénédicte Clarisse; Carine Segura-Dje...; Franka Glöckner; Clara Elia; Stéphane Réhel; Patrice Clochon; Franck Doidy; Julien Chavant; Olivier Etard; Fausto Viader; Jean-Michel Grellard; Justine Lequesne; Florence Joly; Francis Eustache; Tristan Martin; Bénédicte Giffard; Gaëlle Quarck; Joy Perrier
• Keywords: Galvanic vestibular stimulation

Background Patients with breast cancer (BC) exhibit circadian rhythm disruptions, mainly of rest-activity (RAR), which sleep is an essential component, and cortisol rhythm. Sleep complaints such as insomnia cognitive impairments are prevalent in BC. In general population, known to contribute greatly cognition. Thus, improving RAR (and particularly sleep) could help limiting BC patients. It has recently been suggested that, addition its role spatial memory, the vestibular system contributes synchronization. Its stimulation therefore limit both disturbances memory deficits Objectives The main aim ICANSLEEP-2 study assess effects galvanic (GVS) on rhythms. secondary whether GVS improves Methods Two groups (Insomnia Severity Index > 7) will be included: a patients’ group ( n = 50) healthy control without history 25). There two assessment sessions, before after 2 weeks GVS. randomly assigned either or sham (noneffective stimulation). Controls receive quantified compared between groups. Assessments include actigraphy, salivary cortisol, polysomnography, test battery (including computer-based task for memory) validated questionnaires (for psychological functioning complaints). Discussion Current methods have had controversial outcomes regarding structure. We expect offer new mean directly targeting disruptions patients, beneficial Given crucial impact functioning, notably patients should enhance their functioning. Ethics dissemination This received ethical approval from Ile de France IV institutional review board 19 April 2022 (no. ID-RCB: 2022-A00437-36). findings yielded by this protocol presented at various conferences peer-reviewed journals. Clinicaltrials.gov registration number NCT05414357 .